MX2024003886A - Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso. - Google Patents

Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso.

Info

Publication number
MX2024003886A
MX2024003886A MX2024003886A MX2024003886A MX2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical formulation
formulation including
including tacrolimus
tacrolimus
Prior art date
Application number
MX2024003886A
Other languages
English (en)
Spanish (es)
Inventor
Evangelos Karavas
Efthymios Koutris
Lida Kalantzi
Sotiria Chatidou
Nikos Lemonakis
Anna Papadaki
Vincent Brieudes
Artemis Kalezi
Athanasios Katsenis
Katerina Kotti
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100639A external-priority patent/GR1010308B/el
Priority claimed from GB2116138.5A external-priority patent/GB2612779A/en
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Publication of MX2024003886A publication Critical patent/MX2024003886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024003886A 2021-09-27 2022-09-27 Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso. MX2024003886A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20210100639A GR1010308B (el) 2021-09-27 2021-09-27 Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου
GB2116138.5A GB2612779A (en) 2021-11-10 2021-11-10 Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
PCT/EP2022/025445 WO2023046321A1 (en) 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Publications (1)

Publication Number Publication Date
MX2024003886A true MX2024003886A (es) 2024-07-10

Family

ID=83902713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003886A MX2024003886A (es) 2021-09-27 2022-09-27 Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso.

Country Status (10)

Country Link
US (1) US20250319028A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440550A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536879A (cg-RX-API-DMAC7.html)
KR (1) KR20240060874A (cg-RX-API-DMAC7.html)
AU (1) AU2022351126A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233139A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005380A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024003886A (cg-RX-API-DMAC7.html)
WO (1) WO2023046321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202403104B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120000593B (zh) * 2024-12-27 2026-03-20 广东药科大学 一种他克莫司微晶及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060210638A1 (en) 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
EP3439654A4 (en) * 2016-04-05 2020-03-18 The Hospital For Sick Children SYSTEM FOR DELIVERING FK506 TO IMPROVE NERVOUS REGENERATION

Also Published As

Publication number Publication date
EP4440550A1 (en) 2024-10-09
AU2022351126A1 (en) 2024-05-09
US20250319028A1 (en) 2025-10-16
CA3233139A1 (en) 2023-03-30
CO2024005380A2 (es) 2024-05-30
ZA202403104B (en) 2025-01-29
JP2024536879A (ja) 2024-10-08
KR20240060874A (ko) 2024-05-08
WO2023046321A8 (en) 2024-05-30
WO2023046321A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EA201691884A1 (ru) Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения
CY1124369T1 (el) Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης
NZ607797A (en) Corticosteroids for the treatment of joint pain
AR126851A2 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas
EP3753966A4 (en) AMPHIPHILES BLOCK COPOLYMER, MANUFACTURING METHOD FOR THEREFORE AND NANOMICELLAL DRUG LOADING SYSTEM
CO2024005380A2 (es) Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso
MX2022015777A (es) Un proceso para degradar productos de plastico.
ES2721850T3 (es) Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
MX359119B (es) Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas.
CO2019003130A2 (es) Polímeros absorbentes, métodos para su producción y usos de los mismos.
CU20160164A7 (es) Un nanocomplejo micelar
MX2009010907A (es) Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
CY1121660T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων
UY38673A (es) Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista
MX373189B (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación.
BR112018002414A2 (pt) sistema de distribuição de polímero líquido para administração prolongada de fármacos
MX392770B (es) Composición farmacéutica de estabilidad mejorada.
MX2019013345A (es) Métodos para el tratamiento de glioblastoma recurrente (rgbm).
PH12013000124A1 (en) Pharmaceutical microsphere for embolization
CO2024005798A2 (es) Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma
EP4374861A3 (en) A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CL2019000624A1 (es) Formulaciones de buprenorfina de liberación sostenida.
MX2020000377A (es) Esterilizacion mediante radiacion de formas de dosis de polimero hipercomprimido.
AR106085A1 (es) Formulaciones de olanzapina de liberación sostenida
BR112023005552A2 (pt) Composição de copolímero bimodal de poli(etileno-co-1-hexeno), método para produzir a composição de copolímero bimodal de poli(etileno-co-1-hexeno), formulação de polietileno, artigo fabricado, tubulação, e, método para transportar uma substância